Highest-materiality recent filing
Cibus Q1 net loss narrows to $21.2M; Rice HT U.S. launch pushed to 2029
Net loss of $21.2M ($0.33/share) vs $49.4M ($1.34) in Q1 2025; no goodwill impairment this quarter.
Cibus raises ~$13.5M in public offering of 6.98M shares at $2.15/share
Underwritten public offering of 6,976,744 shares of Class A common stock at $2.15 per share.
Cibus Q4 loss $31.9M; cash $9.9M; Jan 2026 offering $22.3M; exploring strategic alternatives
Cash and equivalents $9.9M at Dec 31, 2025; with $19.8M net Jan 2026 offering, runway into late Q3 2026.
Cibus announces public offering of 13.3M shares at $1.50; board members buy 1M shares
Offering of 13,333,333 shares of Class A common stock at $1.50 per share; BTIG sole underwriter.
Cibus Updates Business Outlook in 8-K, Projects >$200M Annual Royalties from Rice Traits
Cibus estimates over $200 million potential annual addressable royalties from Rice herbicide tolerance traits in the US and Latin America.
Cibus Q3 net loss $24.3M; $23.9M cash; signs 7 Rice customers
Net loss $24.3M ($0.44/share) vs $201.5M year-ago which included $181.4M goodwill impairment.
Cibus Q2 net loss narrows to $26.6M; cash runway into Q2 2026; Rice trait commercialization on track
Net loss $26.6M ($0.61 per share) vs $28.5M ($1.14) YoY; R&D $12.2M, SG&A $6.6M, both down on cost cuts.
Cibus prices 15.7M-share public offering at $1.75/share; expected close June 9
Entered Securities Purchase Agreements for 15,714,285 shares at $1.75/share in registered public offering.
Cibus Q1 net loss $49.4M; cash $23.6M into Q3; evaluates strategic alternatives
Net loss of $49.4M ($1.34 per share) vs $27.0M a year ago; includes $21.0M non-cash goodwill impairment.
Cibus Q4 2024 net loss $25.8M; cash $14.4M; reviews strategic alternatives
Q4 2024 net loss $25.8M vs $277.2M in Q4 2023 (prior-year includes $249.4M goodwill impairment); EPS -$0.87 vs -$12.59.
Cibus CEO Rory Riggs resigns; President Peter Beetham named interim CEO
Rory Riggs resigns as CEO, remains Chairman of the Board.
Cibus raises ~$22.6M in registered direct offering; CEO Riggs participates at $2.50/share
Company sells 4,340,000 shares at $2.50 each with common warrants; 4,700,000 pre-funded warrants at $2.4999.
Cibus Q3 net loss $201.5M on $181.4M goodwill impairment; cash runway into late Q1 2025
Net loss $201.5M ($7.63/sh) vs $34.5M ($1.59/sh) YoY; includes $181.4M non-cash goodwill impairment.
Cibus cuts ~26 jobs, initiates cost reduction actions; expects $0.35M in Q4 charges
Workforce reduction of ~26 full-time employees approved Oct 16, communicated Oct 18.
Cibus launches $12M underwritten public offering of 3M shares at $4.00/share
Offering of 3,000,000 shares at $4.00 per share; net proceeds ~$11.2M ($12.8M with overallotment).
Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024
Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).
Cibus raises ~$13M in direct offering; CEO invests at $10.20/unit
Gross proceeds ~$12.98M from sale of 1,298,040 shares and warrants at $10.00 per unit; CEO purchased at $10.20 per unit.
Net loss $27.0M ($1.12 per share) vs $5.4M in prior period; year-over-year not comparable due to business combination.
Cibus Q4 net loss $277M on $249M goodwill impairment; cash $32.7M
Net loss $277.2M ($12.59/share) vs $2.8M prior year, driven by $249.4M non-cash goodwill and intangible impairment.
Cibus estimates $249.4M non-cash impairment charge on goodwill and IPR&D
Goodwill impairment of $150.4M and in-process R&D impairment of $99.0M for fiscal 2023.
Peter Beetham, the Company’s President and Chief Operating Officer, was appointed as Interim Chief Executive Officer
On February 24, 2025, Rory Riggs resigned as the Chief Executive Officer of Cibus, Inc.
On November 18, 2024, the Board of Directors (the “Board”) of Cibus, Inc. (the “Company”) appointed August Moretti to serve as a member of the Board, effective as of such date.
The Company's Board of Directors formally appointed Mr. Broos as the Company's Interim Chief Financial Officer, effective immediately.
Wade King's departure from the role of Chief Financial Officer.
Mr. King notified the Company on August 15, 2024 that he would be stepping down from the role of Chief Financial Officer, effective September 30, 2024.
the Company intends to appoint Carlo Broos, the Company’s Senior Vice President of Finance, to serve as Interim Chief Financial Officer.
Max materiality 0.85 · Median 0.57 · Most common event other_material